A meta-analysis comparing EGFR-TKIs with chemotherapy as second-line therapy for wild-type EGFR lung cancer patients was presented in part at the 2013 ASCO annual meeting and also demonstrated chemotherapy had superiority in PFS over EGFR-TKIs for EGFR M− patients. The gene discussed is EGFR; the disease is lung carcinoma.